ONS in Gastrointestinal Cancer Patients Undergoing Chemotherapy

Sponsor
Beni-Suef University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05980624
Collaborator
(none)
160
1
2
11.4
14

Study Details

Study Description

Brief Summary

The study hypothesizes that the addition of oral nutrition supplement concurrent chemotherapy treatment to the GI cancer patients will improve the prognosis of cancer cachexia, improve health state quality of life and increase chemotherapy tolerance

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: oral nutrition supplement
N/A

Detailed Description

Malnutrition is a major public health issue in low- and middle-income countries and forms part of the United Nations 2030 Agenda for Sustainable Development Goals .Cancer is a systemic disease, since even in the early stages malignancies are accompanied by homeostatic imbalance, including metabolic deregulation and increased catabolism. These abnormalities may initially seem poorly discernible in the clinic, but with disease progression they may aggravate; and may cause overt cancer-related cachexia.GI cancers show higher mortality than any other kind of cancer. In 2020, they accounted for an estimated 3.5 million deaths worldwide, with a further 5.0 million new cases diagnosed in the same year . Colorectal cancer (CRC) is the most common type of GI cancer, being the third most common of all organ cancers after lung and breast cancers, whereas gastric, liver, esophageal, and pancreatic cancers are ranked the fifth, sixth, eighth, and 12th most commonly diagnosed cancers, respectively

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
The Impact of Oral Nutrition Supplements on the Clinical Outcomes in Gastrointestinal Cancer Patients Undergoing Chemotherapy
Actual Study Start Date :
Jul 20, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Group A

nutrition counselling plus Standard chemotherapy only. Patients will undergo only standard chemotherapy for 3 months

Experimental: Group B

nutrition counselling plus standard chemotherapy adding oral nutrition supplements as described in manufacturer label daily for 3 month and

Dietary Supplement: oral nutrition supplement
patients receive ONS 300kcal in daily basis

Outcome Measures

Primary Outcome Measures

  1. Body Composition [3 month]

    measured by DEXA OR BIA

  2. Anthropometric measures [3 month]

    Body mass index change

  3. Nutrition status - scored Patient-Generated Subjective Global Assessment (PG-SGA) [3 MONTHS]

    malnutrition assessment tool. ( 0-1 )No intervention required at this time. Re-assessment on routine and regular basis during treatment. (2-3) Patient & family education by dietitian, nurse, or other clinician with pharmacologic intervention as indicated by symptom survey and lab values as appropriate. (4-8) Requires intervention by dietitian, in conjunction with nurse or physician as indicated by symptoms . 9 Indicates a critical need for improved symptom management and/or nutrient intervention options

Secondary Outcome Measures

  1. Laboratory data values mean and standard deviation [3 months]

    Albumin and CRP ,total protein

  2. overall response rate [6 months]

    complete response or progression and regression percentage of participants

  3. common adverse effects [6 months]

    Git toxicity , hematologic toxicity

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
GI cancer patients will be included in the study if they meet the following criteria:
  1. Confirmed cancer diagnosis any stage or metastatic confirmed by radiological and pathological or by clinical evaluation receiving neo/adjuvant chemotherapy treatment.

  2. Age above 18 years old

  3. Be accessible for chemotherapy treatment and follow-up

  4. Availability to administer oral supplements

  5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2

  6. Life expectancy ≥3 months.

  7. Written informed consent according to the local Ethics Committee requirements

  8. Willing to fill Nutrition questionnaires.

  9. Negative pregnancy test for pre-menopausal women before inclusion in the trial

Exclusion Criteria:
  • The patients will be excluded from the study if they have the following criteria:
  1. Known hypersensitivity reaction to the investigational compounds or incorporated substances

  2. patients who are unlikely to comply with trial requirements (eg, confusion, psychological or mood disturbances ,alcoholism)

  3. Pregnancy or lactating

  4. Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent

  5. Age < 18 years

  6. Indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume ONS

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beni suef university hospital Banī Suwayf Egypt

Sponsors and Collaborators

  • Beni-Suef University

Investigators

  • Principal Investigator: Alshaimaa Rabie, Beni-Suef University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ALshaimaa Ibrahim Rabie, Clinical nutrition pharmacist, Beni-Suef University
ClinicalTrials.gov Identifier:
NCT05980624
Other Study ID Numbers:
  • FMBSUREC/09072023/Rabie
First Posted:
Aug 8, 2023
Last Update Posted:
Aug 8, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 8, 2023